Fulgent Genetics to Participate in 2017 BTIG Medical Technology, Life Science and Diagnostic Tools Conference

TEMPLE CITY, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ:FLGT) today announced that Ming Hsieh, Chairman and Chief Executive Officer, and Paul Kim, Chief Financial Officer, are scheduled to participate in the 2017 BTIG Medical Technology, Life Science and Diagnostic Tools Conference on Wednesday, March 1, 2017 in Snowbird, Utah.

BTIG’s annual conference consists of a series of one-on-one meetings and will not be webcast.

About Fulgent Genetics

Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provde physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 300 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.

Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633, [email protected]
Chris Danne, 415-217-5865, [email protected]

[ Back To TMCnet.com's Homepage ]